Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference December 1, 2009

[Guest guest]

http://www.prnewswire.com/news-releases/anadys-pharmaceuticals-to-present-at-the\

-piper-jaffray-healthcare-conference-72856012.html

Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference

SAN DIEGO, Nov. 24 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc.

(Nasdaq: ANDS) announced today that it will present at the 21st Annual Piper

Jaffray Healthcare Conference on Tuesday, December 1, 2009 at 9:00 a.m. EST

(6:00 a.m. PST). The conference is being held at The New York Palace Hotel.

Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will

provide an overview of Anadys and its clinical development programs, ANA598 and

ANA773.

The corporate presentation will be simultaneously webcast and can be accessed on

the Investor Relations page of the Company's website at www.anadyspharma.com.

Listeners are encouraged to visit the website approximately five minutes prior

to the corporate presentation to download or install any necessary software. A

replay of the presentation will be available approximately one hour after the

live webcast concludes and will be available through December 15, 2009.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to

improving patient care by developing novel medicines for the treatment of

hepatitis C. The Company believes hepatitis C represents a large unmet medical

need in which meaningful improvements in treatment outcomes may be attainable

with the introduction of new medicines. The Company is developing ANA598, a

non-nucleoside polymerase inhibitor for the treatment of hepatitis C. The

Company has also investigated the potential of ANA773, an oral, small-molecule

inducer of endogenous interferons that acts via the Toll-like receptor 7, or

TLR7, pathway in hepatitis C.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature

constitute " forward-looking statements. " Such statements include, but are not

limited to, references to Anadys' strategy, development programs, and ability to

develop novel medicines for the treatment of hepatitis C. Such forward-looking

statements involve known and unknown risks, uncertainties and other factors,

which may cause Anadys' actual results to be materially different from

historical results or from any results expressed or implied by such

forward-looking statements. For example, the results of preclinical and early

clinical studies may not be predictive of future results, and Anadys cannot

provide any assurances that ANA598 or ANA773 will not have unforeseen safety

issues, will have favorable results in ongoing or future clinical trials or will

receive regulatory approval. Risk factors that may cause actual results to

differ are more fully discussed in Anadys' SEC filings, including Anadys' Form

10-K for the year ended December 31, 2008 and Anadys' Form 10-Q for the quarter

ended September 30, 2009. All forward-looking statements are qualified in their

entirety by this cautionary statement. Anadys is providing this information as

of this date and does not undertake any obligation to update any forward-looking

statements contained in this document as a result of new information, future

events or otherwise.

SOURCE Anadys Pharmaceuticals, Inc.